Multiplexed fluorescence in situ hybridization–based circulating tumor cell (CTC) technology detects cytogenetic abnormalities in patients who are at risk for non–small cell lung cancer with high accuracy. Combined with low‐dose computed tomography, this CTC technology can efficiently rule out malignancy in at‐risk patients with benign pulmonary nodules.